Literature DB >> 7923547

Hypoxia and drug resistance.

B A Teicher1.   

Abstract

Biologically and therapeutically important hypoxia occurs in many solid tumor masses. Hypoxia can be a direct cause of therapeutic resistance because some drugs and radiation require oxygen to be maximally cytotoxic. Cellular metabolism is altered under hypoxic conditions. Hypoxia can result in drug resistance indirectly if under this condition cells more effectively detoxify the drug molecules. Finally, there is evidence that hypoxia can enhance genetic instability in tumor cells thus allowing more rapid development of drug resistance cells. The current review describes the effects of hypoxia on tumor response to a variety of anti-cancer agents and also describes progress toward therapeutically useful methods of delivering oxygen to tumors in an effort to overcome therapeutic resistance due to hypoxia. Finally, the use of hypoxic cell selective cytotoxic agents as a means of addressing hypoxic 'drug resistance' is discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923547     DOI: 10.1007/bf00689633

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  218 in total

1.  DNA topoisomerases as targets for cancer therapy.

Authors:  W E Ross
Journal:  Biochem Pharmacol       Date:  1985-12-15       Impact factor: 5.858

2.  Enhancement of mitomycin C cytotoxicity to hypoxic tumor cells by dicoumarol in vivo and in vitro.

Authors:  S R Keyes; S Rockwell; A C Sartorelli
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

3.  Poduction of free radicals from phenol and tocopherol by bleomycin-iron(II) complex.

Authors:  Y Sugiura
Journal:  Biochem Biophys Res Commun       Date:  1979-03-30       Impact factor: 3.575

4.  Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts.

Authors:  D K Kalwinsky; A T Look; J Ducore; A Fridland
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

5.  Hyperbaric oxygen and radiobiology of a C3H mouse mammary carcinoma.

Authors:  H D Suit; M Maeda
Journal:  J Natl Cancer Inst       Date:  1967-10       Impact factor: 13.506

6.  Preferential activation of mitomycin C to cytotoxic metabolites by hypoxic tumor cells.

Authors:  K A Kennedy; S Rockwell; A C Sartorelli
Journal:  Cancer Res       Date:  1980-07       Impact factor: 12.701

Review 7.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

Authors:  P Vaupel; F Kallinowski; P Okunieff
Journal:  Cancer Res       Date:  1989-12-01       Impact factor: 12.701

8.  Schedule dependent tumour growth delay, DNA cross-linking and pharmacokinetic parameters in target tissues with cis-diamminedichloroplatinum(II) and etanidazole with or without hyperthermia or radiation.

Authors:  B A Teicher; M R Pfeffer; E Alvarez Sotomayor; T S Herman
Journal:  Int J Hyperthermia       Date:  1991 Sep-Oct       Impact factor: 3.914

9.  Response of aerobic and hypoxic cells in a solid tumor to adriamycin and cyclophosphamide and interaction of the drugs with radiation.

Authors:  I Tannock
Journal:  Cancer Res       Date:  1982-12       Impact factor: 12.701

10.  RSU 1069, a 2-nitroimidazole containing an alkylating group: high efficiency as a radio- and chemosensitizer in vitro and in vivo.

Authors:  G E Adams; I Ahmed; P W Sheldon; I J Stratford
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

View more
  128 in total

Review 1.  FDG-PET in monitoring therapy of breast cancer.

Authors:  H-J Biersack; H Bender; H Palmedo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-27       Impact factor: 9.236

2.  Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy.

Authors:  Davide Franceschini; Fabiola Paiar; Calogero Saieva; Pierluigi Bonomo; Benedetta Agresti; Icro Meattini; Daniela Greto; Monica Mangoni; Fiammetta Meacci; Mauro Loi; Giacomo Zei; Lorenzo Livi; Giampaolo Biti
Journal:  Radiol Med       Date:  2015-09-24       Impact factor: 3.469

Review 3.  In Vivo pO2 Imaging of Tumors: Oxymetry with Very Low-Frequency Electron Paramagnetic Resonance.

Authors:  Boris Epel; Howard J Halpern
Journal:  Methods Enzymol       Date:  2015-09-26       Impact factor: 1.600

Review 4.  Redox activation of metal-based prodrugs as a strategy for drug delivery.

Authors:  Nora Graf; Stephen J Lippard
Journal:  Adv Drug Deliv Rev       Date:  2012-01-25       Impact factor: 15.470

5.  Three-dimensional neuroblastoma cell culture: proteomic analysis between monolayer and multicellular tumor spheroids.

Authors:  Hari R Kumar; Xiaoling Zhong; Derek J Hoelz; Frederick J Rescorla; Robert J Hickey; Linda H Malkas; John A Sandoval
Journal:  Pediatr Surg Int       Date:  2008-09-17       Impact factor: 1.827

6.  A proteomic investigation into adriamycin chemo-resistance of human leukemia K562 cells.

Authors:  Xingchen Peng; Fengming Gong; Gang Xie; Yuwei Zhao; Minghai Tang; Luoting Yu; Aiping Tong
Journal:  Mol Cell Biochem       Date:  2011-01-18       Impact factor: 3.396

Review 7.  Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response.

Authors:  S R McKeown
Journal:  Br J Radiol       Date:  2014-03       Impact factor: 3.039

8.  Influence of hypoxia-related genetic polymorphisms on the prognosis of patients with metastatic gastric cancer treated with EOF.

Authors:  Wenbo Tang; Xin Liu; Lixin Qiu; Xiaoying Zhao; Mingzhu Huang; Jiliang Yin; Jin Li; Weijian Guo; Xiaodong Zhu; Zhiyu Chen
Journal:  Oncol Lett       Date:  2017-11-15       Impact factor: 2.967

Review 9.  Positron emission tomography to assess hypoxia and perfusion in lung cancer.

Authors:  Eline E Verwer; Ronald Boellaard; Astrid Am van der Veldt
Journal:  World J Clin Oncol       Date:  2014-12-10

10.  Correlation of P-glycoprotein expression with poor vascularization in human gallbladder carcinomas.

Authors:  Yu Tian; Li-Li Zhu; Ren-Xuan Guo; Chui-Feng Fan
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.